Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes

Table 1 Patient characteristics and results before correcting for potential confounding factors

	SGLT2	Control
n	46909	189120
Mean age	59	66
SD age	11	13
Percent male	53%	52%
Comorbidities
Hypertension (I10)	45%	41%
CKD (N18)	4%	8%
Co-medication
On insulin	32%	19%
On metformin	52%	33%
LDL cholesterol (mg/dL)	91.6	93.1
HDL cholesterol (mg/dL)	43.6	43.2
After index event
Total stroke (I63) or MI (I21)	12347 (5.2%)
n in group	1667	10680
Percent in group	3.60%	5.60%
RR SGLT2 vs control	0.63

SGLT2: Sodium-glucose co-transporter-2; RR: Risk ratio; SD: Standard deviation; CKD: Chronic kidney disease; LDL: Low density lipoprotein; HDL: High density lipoprotein; MI: Myocardial infarction.

Table 2 Results from the patient subgroups (strata) with potential confounding factors

	Stratum 1 > 60 yr		Stratum 2 hypertension		Stratum 3 CKD		Stratum 4 insulin		Stratum 5 metformin
	SGLT2	control	SGLT2	control	SGLT2	control	SGLT2	control	SGLT2	control
n	23594	131219	27499	115703	3786	34388	24395	90978	37762	136569
patients with stroke or MI	9784 (6.3%)		10827 (7.6%)		4755 (12.5%)		8976 (7.8%)		8629 (4.9%)
n in group	1077	8707	1452	9375	391	4364	1275	7701	1394	7235
percent in group	4.60%	6.60%	5.30%	8.10%	10.30%	12.70%	5.20%	8.50%	3.70%	5.30%
RR SGLT2 vs control	0.69		0.65		0.81		0.62		0.7

SGLT2: Sodium-glucose co-transporter-2; MI: Myocardial infarction; RR: Risk ratio; CKD: Chronic kidney disease.

Table 3 Data density in the two comparator cohorts

	SGLT2	Control
Total facts	54852092	261813664
Avg facts per patient	1143	1325
Avg diagnosis facts per patient	231	262
Eastern United States, patients (%)	68	69
Western United States, patients (%)	32	31

SGLT2: Sodium-glucose co-transporter-2; Avg: Average.